Reported about 1 month ago
The Drug Enforcement Administration (DEA) has scheduled a hearing for December 2, 2024, to consider reclassifying marijuana as a Schedule 1 drug, which will follow the upcoming presidential election. This announcement has prompted declines in cannabis stocks, including Curaleaf, Tilray, Green Thumb, Cresco Labs, and Verano Holdings.
Source: YAHOO